Dr. Leen Kawas Discusses The U.S. Biotechnology Industry’s Changing Dynamics And Offers 5 Strategic Recommendations For 2025
In 2024, the biotech market is projected to grow to USD 1.76 trillion before reaching a 2030 valuation of USD 3.88 trillion. For reference, the 2024 to 2030 period is expected to display a 13.96% Compound Annual Growth Rate (or CAGR).
Author:Daniel JamesReviewer:Anderson PattersonSep 06, 20241.1K Shares35.7K Views
The global biotechnology industry’s expansion continues at a rapid pace. In 2023, respected market intelligence firmGrand View Researchvalued the global biotech market at USD 1.55 trillion. In 2024, the biotech market is projected to grow to USD 1.76 trillion before reaching a 2030 valuation of USD 3.88 trillion. For reference, the 2024 to 2030 period is expected to display a 13.96% Compound Annual Growth Rate (or CAGR).
The United States biotech industry will play a key role in these global expansion predictions. In fact, United States biotech firms collectively comprise a major portion of the global market. That said, the U.S. biotech landscape continues to undergo a foundational realignment that will affect every biotech industry company.
Dr. Leen Kawas’ Multifaceted Biotech Industry Experience
Leen Kawas, Ph. D. is Propel Bio Partners’ Managing General Partner. This Los Angeles-based biotech venture capital firm partners with biotech start-ups and early-stage companies requiring financial, operations, and technical expertise. Dr. Leen Kawas seeks candidates offering innovative solutionsto a widespread problem. A strong diversity advocate, she encourages pitches from women and minority applicants.
Prior to her current role, Dr. Leen Kawas excelled as Athira’s Chief Executive Officer (or CEO). During her time at the firm, she oversaw several productive drug development cycles. With her biotech expertise as a backdrop, Dr. Kawas provided insights on the industry’s changing dynamics. She also discussed five strategic recommendations biotech firms should consider in 2025.
The U.S. Biotech Industry Undergoes A Significant Realignment
The United States biotechnology industry continues to undergo a substantial realignment that affects many biotechs’ operations and investment prospects. In August 2024, theBioSpacedigital news hub discussed the industry-wide doldrums that followed the COVID-19 pandemic biotech market uptick.
Today, the United States biotech industry is recovering with strategic realignments on multiple fronts. Dr. Leen Kawas discussed these developments, which will likely affect newer biotech firms along with established industry leaders.
Biotech Firms’ COVID-19 Era Rise And Fall
During the COVID-19 pandemic’s early months, many biotech firms were engaged in developing potential vaccines and/or other targeted therapies. Naturally, these large-scale efforts caught investors’ attention, driving huge cash infusions that would ideally bring good returns on investment.
Concurrently, low interest rates incentivized some biotechs to assume more debt. During 2021, biotech firms completed 170 initial public offerings (or IPOs) compared to an annual average of approximately 36 IPOs. Together, both developments often sparked sky-high biotech company valuations based on a firm’s future potential rather than current realities.
The Bottom Falls Out
In late 2021, however, potential customers began to lose interest in COVID-19 products. The sector’s surprisingly sluggish sales threw the United States biotech market into organizational and financial chaos.
Rising interest rates in 2022, and less debt financing throughout 2023, left many biotech businesses with a shortage of operations and research capital. As they sought to remain afloat, bankruptcies and restructurings increased. During the same period, most IPOs were paused in this unfavorable financial environment.
2024’s Changing Biotech Industry Dynamics
In 2024, the United States biotech industry continues to adapt to an evolving business landscape. Strong merger and acquisition activity signals that numerous consolidations are underway. Dr. Leen Kawas noted that initial public offerings have also increased, and more IPOs could be on the horizon.
Additionally, increasingly optimistic investors are focused on innovation and “out of the box” business strategies. Investors are also attracted to biotech businesses with encouraging drug and/or therapy development outcomes. Finally, large pharmaceutical companies continue to seek brand-new public biotechs with promising clinical trial results.
5 Strategic Recommendations For 2025
The U.S. biotechnology industry’s changing dynamics, along with investors’ strategic realignments, indicate that biotech firms should reevaluate their priorities. Dr. Leen Kawas highlighted five strategies biotechs should consider in 2025.
Practice Out-of-the-Box Research And Development
Biotech companies’ research and development (or R&D) programs continue to produce wide-ranging results. Most prominently, artificial intelligence (or AI) and machine learning (a form of AI) technologies continue to show promise for numerous applications. These tools have already decreased the time required for drug discovery and related drug development processes. Other R&D breakthroughs lead to targeted disease treatments and other beneficial therapies.
From a business perspective, investors often seek out biotechs that utilize unconventional approaches and achieve truly remarkable outcomes. Specifically, venture capital firms (such as Propel Bio Partners) actively look for candidates with demonstrated positive results.
Integrate Digital Health Technologies And AI Applications
Biotech companies should continue to incorporate digital health technologies and artificial intelligence (or AI) tools into the business’ operations. This strategy enhances efficiency while furthering the company’s digital transformation goals. Besides the patient-centric functionalities, improved healthcare provider communication enables better-coordinated and more cost-effective patient care.
Adopt Well-Thought Commercialization Strategies
Biotechs with approved drugs and therapies should ensure they formulate a comprehensive marketplace introduction strategy. The process should begin with an exhaustive market analysis. Next, pricing schemes should be accompanied by programs that ensure the treatments are accessible to patients who need them.
To ensure ongoing investor support, biotechs’ milestone-driven funding agreements require effective strategic planning and well-thought project management. As Propel Bio Partners’ Managing General Partner, Dr. Leen Kawas often assists biotech clients in meeting these challenges.
Forge Multiple Strategic Partnerships
Biotech businesses continue to benefit from well-planned strategic alliances. Partnering with pharmaceutical companies, technology firms, and academic institutions enables mutually beneficial resource sharing. In turn, this drives innovation and facilitates an improved market reach. Equally importantly, these partnerships can help biotechs navigate an increasingly complex regulatory landscape.
Practice Regulatory Advocacy And Compliance
Biotechs should take a proactive approach toward regulatory issues. First, companies should remain aware of ever-changing regulations that could affect their products and the business’ operations. Failing to do so could be an expensive mistake.
In addition, biotech businesses should approach regulatory bodies with a collaborative mindset rather than an adversarial one. By partnering with the U.S. Food and Drug Administration (or FDA) and other relevant entities, biotechs are more likely to adhere to compliance standards. Dr. Leen Kawas took this approach while managing Athira’s drug development cycles.
Biotechs’ compliant behavior positions the companies to help shape policies pertaining to patient therapies. These proactive strategies also improve biotechs’ chances of navigating future regulatory obstacles. In turn, these successes help facilitate a more favorable funding environment.
Fluid Biotech Industry Dynamics Can Lead To Solid Opportunities
The United States biotechnology industry’s changing dynamics continue to affect companies of all sizes and business stages. That said, Dr. Leen Kawasemphasized that biotechs with solid foundations and robust R&D programs are well-positioned for success in this revamped business environment.
Daniel James
Author
Daniel James is a distinguished gerontologist, author, and professional coach known for his expertise in health and aging.
With degrees from Georgia Tech and UCLA, including a diploma in gerontology from the University of Boston, Daniel brings over 15 years of experience to his work.
His credentials also include a Professional Coaching Certification, enhancing his credibility in personal development and well-being.
In his free time, Daniel is an avid runner and tennis player, passionate about fitness, wellness, and staying active.
His commitment to improving lives through health education and coaching reflects his passion and dedication in both professional and personal endeavors.
Anderson Patterson
Reviewer
Anderson Patterson, a tech enthusiast with a degree in Computer Science from Stanford University, has over 5 years of experience in this industry.
Anderson's articles are known for their informative style, providing insights into the latest tech trends, scientific discoveries, and entertainment news.
Anderson Patterson's hobbies include exploring Crypto, photography, hiking, and reading.
Anderson Patterson's hobbies include exploring Crypto, photography, hiking, and reading.
In the Crypto niche, Anderson actively researches and analyzes cryptocurrency trends, writes informative articles about blockchain technology, and engages with different communities to stay updated on the latest developments and opportunities.
Latest Articles
Popular Articles